Galapagos NV (NASDAQ:GLPG) and Ryvu Therapeutics announce a collaboration focused on the discovery and development of novel small molecule drugs in inflammation.
The collaboration is based on a novel drug target
identified by Ryvu, which will contribute its technology platform and
related intellectual property (IP).
Under the terms of the agreement, Ryvu is
responsible for early drug discovery, and Galapagos will have an
exclusive option to license IP developed by Ryvu and will be responsible
for all further development of the program.
Ryvu will receive an upfront payment and will be eligible for further option, milestone and royalty payments.
https://seekingalpha.com/news/3561183-galapagos-teams-up-ryvu-therapeutics-in-inflammation
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.